Celldex Therapeutics Stock Filter Stocks by Fundamentals
| CLDX Stock | USD 27.02 0.80 3.05% |
Celldex Therapeutics fundamentals help investors to digest information that contributes to Celldex Therapeutics' financial success or failures. It also enables traders to predict the movement of Celldex Stock. The fundamental analysis module provides a way to measure Celldex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celldex Therapeutics stock.
Celldex | Shares Owned by Institutions |
Celldex Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Celldex Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Celldex Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Celldex Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Celldex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Celldex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Celldex Therapeutics' value.| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.5 M | Commodore Capital Lp | 2024-06-30 | 1.4 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.4 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.4 M | Jennison Associates Llc | 2024-09-30 | 1.3 M | Novo A/s | 2024-09-30 | 963.7 K | Goldman Sachs Group Inc | 2024-06-30 | 874.2 K | Wellington Management Company Llp | 2024-06-30 | 8.1 M | Fmr Inc | 2024-09-30 | 6 M |
Celldex Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (16.34) % | ||||
| Current Valuation | 986.63 M | ||||
| Shares Outstanding | 66.34 M | ||||
| Shares Owned By Institutions | 99.69 % | ||||
| Number Of Shares Shorted | 8.24 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 2.28 X | ||||
| Price To Sales | 179.69 X | ||||
| Revenue | 6.88 M | ||||
| Gross Profit | (79.9 M) | ||||
| EBITDA | (139.03 M) | ||||
| Net Income | (141.43 M) | ||||
| Cash And Equivalents | 356.82 M | ||||
| Cash Per Share | 7.63 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.29 X | ||||
| Book Value Per Share | 11.85 X | ||||
| Cash Flow From Operations | (107.29 M) | ||||
| Short Ratio | 9.03 X | ||||
| Earnings Per Share | (2.58) X | ||||
| Target Price | 67.1 | ||||
| Number Of Employees | 160 | ||||
| Beta | 1.59 | ||||
| Market Capitalization | 1.79 B | ||||
| Total Asset | 465.63 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 400.57 M | ||||
| Current Asset | 294.94 M | ||||
| Current Liabilities | 30.24 M | ||||
| Net Asset | 465.63 M |
About Celldex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celldex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.